Patents by Inventor Steven R. Roffler

Steven R. Roffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-specific antibodies and uses thereof
    Patent number: 11369690
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 28, 2022
    Assignee: ACADEMIA SINICA & KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • Bi-specific antibodies and uses thereof
    Patent number: 11040111
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 22, 2021
    Assignees: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • BI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20210154319
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: August 24, 2018
    Publication date: May 27, 2021
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
  • BI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20200061205
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 27, 2020
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R. ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, KUO-HSIANG CHUANG
  • Bi-specific antibodies and uses thereof
    Patent number: 10188742
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: January 29, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • BI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20190022245
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: August 24, 2018
    Publication date: January 24, 2019
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
  • BI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20170056523
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: March 2, 2015
    Publication date: March 2, 2017
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
  • Preparation of anti-PEG antibody expressing cell and application thereof
    Patent number: 9329180
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 3, 2016
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
  • PREPARATION OF ANTI-PEG ANTIBODY EXPRESSING CELL AND APPLICATION THEREOF
    Publication number: 20140038208
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 6, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: TIAN-LU CHENG, STEVEN R. ROFFLER, KUO-HSIANG CHUANG, SSU-JUNG LU
  • ANTI-POLYETHYLENE GLYCOL ANTIBODY EXPRESSING CELL QUANTIFY ANY FREE POLYETHYLENE GLYCOL AND POLYETHYLENE GLYCOL-DERIVATIZED MOLECULES
    Publication number: 20120015380
    Abstract: In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH3O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: February 22, 2011
    Publication date: January 19, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu